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Host-rangeModiﬁed vaccinia virus Ankara (MVA) was generated by serial passaging in chicken embryo ﬁbroblasts.
During this attenuation, MVA lost the capacity to productively grow in human and most other mammalian
cell lines, as well as acquiring a multitude of deletions and mutations in the MVA genome. This means that
the precise molecular basis for the MVA host-range restriction is still unknown. The vaccinia virus (VACV)
genes F11L and K1L are mutated or truncated in MVA. F11L was previously implicated in VACV-induced cell
motility and virion maturation. Here, we demonstrate that the restoration of F11L gene expression in MVA
rescued virus-induced cell motility, but had no impact on MVA virion maturation and host-range restriction.
Additional insertion of the K1L gene, which restores MVA replication in RK-13 cells, was not sufﬁcient to
extend MVA growth capacity to other mammalian cells.izin und Zoonosen, Ludwig-
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Modiﬁed vaccinia virus Ankara (MVA) is a highly attenuated strain
of vaccinia virus (VACV) that originally served as a candidate vaccine
in Germany to improve the safety of smallpox vaccination (Stickl and
Hochstein-Mintzel, 1971; Stickl, 1974). MVA was obtained by serial
passaging of the ancestor chorioallantois vaccinia virus Ankara (CVA)
in chicken embryo ﬁbroblasts (CEF) (Mayr and Munz, 1964; Mayr,
1976) and its genome contains substantial genetic alterations adding
up to a total loss of about 30 kb of DNA (Meyer et al., 1991). Deletions
and mutations affect many regulatory virus genes likely involved in
VACV host cell interaction and immune evasion (Antoine et al., 1998).
The phenotypic consequence is that MVA is replication defective in
most human and other mammalian cell lines (Carroll andMoss, 1997;
Drexler et al., 1998). While the cascade-like pattern of viral early,
intermediate and late gene expression, including DNA replication, is
still active, viral multiplication is arrested at a late stage leading to
accumulation of immature particles (Sutter and Moss, 1992). This
unique phenotype, which allows high expression of recombinant
antigens without virus replication, makes MVA a safe and efﬁcient
candidate vector for therapeutic vaccines against infectious diseases
and cancer (Sutter and Staib, 2003). However, the mechanism andgenetic basis underlying MVA's restricted replication are not
understood.
VACV has a broad host-range and can productively infect cells
from many vertebrate animal species. VACV host tropism is linked to
the function of so-called viral host-range genes, which when
inactivated cause host-range restrictions. A number of VACV genes
have been associated with host-range phenotypes, the most impor-
tant being the genes K1L, and C7L (Werden et al., 2008). Restoration of
K1L in MVA or its expression in MVA infected cells expands the host-
range of MVA to rabbit kidney-13 (RK-13) cells, but not to other
mammalian cell lines analyzed so far (Carroll and Moss, 1997).
Both K1L and C7L are important for growth of VACV inmammalian
cells, since mutant viruses with inactivated K1L and C7L genes
replicate abortively in many mammalian cells. However, each gene
can compensate for the other and rescue the growth capacity of
deletion mutant viruses (Perkus et al., 1990). The molecular functions
of these VACV host-range gene products are largely unknown. The
K1L gene encodes a 32 kDa ankyrin repeat protein that was previously
shown to prevent activation of host NFκB (Shisler and Jin, 2004), and
to interact with ACAP2, a GTPase activating protein (GAP) for ADP-
ribosylation factor 6 (Arf6) (Bradley and Terajima, 2005). Recently, K1
was also described to prevent protein kinase R (PKR) mediated
phoshorylation of eukaryotic translation initiation factor 2 alpha
(eIF2α), which is a typical interferon effector function (Backes et al.,
2010; Willis et al., 2009). However, neither interaction nor inhibition
of the PKR-eIF2α pathway appears to be essential for the host-range
determining function of K1L (Meng and Xiang, 2006), which is
possibly associated with inhibition of other type I interferon response
effector(s) (Meng et al., 2009).
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(ORF) for C7L is fully conserved (Antoine et al., 1998). Thus, (an)other
unknown viral host-range regulator(s) must be impaired to result in
theMVA growth restriction in mammalian cells. In an early attempt to
address this question, Wyatt et al. (1998) performed genome-wide
marker rescue experiments using DNA from the ancestor VACV
Ankara and identiﬁed a left-side region of the MVA genome as
containing additional fragmented host-range genes, speciﬁcally
suggesting the ORFs F5L, F11L and O1L as candidates.
While O1L and F5L are VACV genes with unknown functions, F11L
encodes a protein able to inhibit host RhoA downstream signaling
pathways and induce motility of VACV infected cells (Valderrama
et al., 2006; Arakawa et al., 2007). Interestingly, knock-down of F11L
expression in VACV stain Western Reserve (VACV WR) infected HeLa
cells resulted in accumulation of immature virions resembling those
observed in MVA infected HeLa cells (Sutter and Moss, 1992;
Valderrama et al., 2006). In addition, a mutant VACV WR F11L-
deletion virus showed a smaller plaque size phenotype upon infection
of monkey BSC-40 cells (Morales et al., 2008) or BS-C-1 cells (Cordeiro
et al., 2009). These observations prompted us to assess whether
impaired F11L function contributes to the restricted host-range of
MVA.
After removing the fragmented F11L gene locus from the MVA
genome we reinserted a functional F11L gene alone, or in combination
with K1L, and tested the resulting viruses upon infection of permissive
and non-permissive cells. Restoration of F11L rescued the motility of
MVA infected cells, conﬁrming that the reinserted F11L gene product
functioned properly. However, infections with recombinantMVA-F11L,
MVA-F11L-K1L or wild-type MVA revealed highly comparable replica-
tive capacities and indistinguishable phenotypes of virion mor-
phogenesis. This demonstrates that restoring F11L alone or combined
with K1L does not sufﬁce to relieve the host-range restriction of MVA.
Results
Reinsertion of the F11L gene into the MVA genome
To test whether the absence of functional F11L is responsible for
MVA's replication defect in mammalian cells, we reintroduced an
intact F11L ORF into the MVA genome. Large parts of the F11L coding
sequence are still present in the MVA genome, but due to a point
mutation and two further deletions the gene is defective and probably
translates a small aberrant protein (Fig. 1A).
We ﬁrst generated a MVA deletion mutant lacking most of the
genomic F11L sequence but preserving 89 bp at its 5′-end to retain the
adjacent late promoter sequence of the essential F10L gene (Lin and
Broyles, 1994). This virus is referred to as MVAΔF11L (Fig. 1B). In a
second step, a wild-type copy of F11L including its authentic promoter
sequence, ampliﬁed by PCR from VACVWRDNA, was inserted into the
deletion III region of MVAΔF11L, resulting in the recombinant virus
MVA-F11L (Fig. 1B).
Restoration of the VACV host-range gene K1L extends MVA
growth capacity to rabbit RK-13 cells (Meyer et al., 1991; Sutter et
al., 1994). Thus, we additionally generated a recombinant virus
carrying the complete sequences for both F11L and K1L (MVA-F11L-
K1L) inserted into the deletion III region (Fig. 1B) in order to test the
possibility that both genes are needed to reconstitute MVA
replication competence in mammalian cells. A comparable recom-
binant MVA virus carrying only the sequences for K1L, (MVA-K1L)
served as a control. We checked the genetic features of these
mutant/recombinant MVA viruses by PCR analyses of viral DNA
prepared from infected HeLa cells (Fig. 1C). Primers annealing to
sequences in F11L that are deleted in the MVA genome (Fig. 1A)
conﬁrmed insertion of the full-length F11L gene into the genome of
MVA-F11L-K1L and MVA-F11L (Fig. 1C, top panel). Using ﬂanking
primers binding upstream and downstream of the original F11Llocus, we conﬁrmed deletion of residual F11L sequences in
MVAΔF11L and the related viruses MVA-F11L-K1L and MVA-F11L
(Fig. 1C, middle panel). Finally, co-insertion of the VACV K1L gene
was analyzed with primers annealing within the K1L ORF present in
MVA-F11L-K1L and MVA-K1L (Fig. 1C, bottom panel).
To monitor for synthesis of the corresponding proteins, we tested
lysates from infected HeLa cells by Western blotting using antibodies
directed against VACV F11 and K1 proteins (Fig. 1D). As expected, the
MVA recombinant viruses produced F11 and K1 proteins in amounts
comparable to the control virus. Sequence analysis (Poxvirus
Bioinformatics Resource Center, www.poxvirus.org) suggested con-
servation of the 95N-terminal amino acids of the MVA F11 protein
including one of the peptides we had used for immunization to
generate F11 speciﬁc antibodies. However, we failed to detect a
corresponding small aberrant F11 protein in Western blot analysis of
lysates from MVA infected cells (data not shown) implying that this
protein is instable or not recognized by our antibodies.
MVA-F11L infection induces cell motility
F11L gene function is necessary to support motility of VACV WR-
infected cells as demonstrated in tissue culture by a wound healing
assay (Valderrama et al., 2006). This assay determines the capacity of
a virus to induce migration of infected cells into a deﬁned cell-free
area generated by scratching a conﬂuent cell monolayer with a pipette
tip to create a “wound”. Conﬂuent BS-C-1 cell monolayers were
infected at a multiplicity of infection (MOI) of 10 with MVA-F11L,
MVA-F11L-K1L, VACV WR and MVA. Deﬁned wound areas were
selected and documented by photography 0 and 24 hours post
infection (hpi). Clearly, more BS-C-1 cells moved into the wound
area when infected with recombinant MVA carrying a functional F11L
gene (MVA-F11L and MVA-F11L-K1L) compared to MVA infected
cells, but VACV WR infection resulted in even higher levels of cell
motility (Fig. 2A). These differences were statistically signiﬁcant, and
suggest that despite regaining F11L function the motility of MVA
infected cells remains slightly impaired, while additional expression
of K1L had no inﬂuence on motility (Fig. 2B).
To assess another implication of F11 function, we monitored the
rearrangement of actin ﬁlaments after VACV infection. Recently, it was
observed that F11L expression coincides with loss of central actin
stress ﬁbers within the ﬁrst few hours post VACV infection (Morales
et al., 2008). In MVA or mock infected cells the whole cell body is
crossed by actin stress ﬁbers, whereas in VACVWR-infected cells actin
ﬁlaments are concentrated at the cell's edge. We infected HeLa cells
with MVA, MVA-F11L and VACV WR at a MOI of 20 and stained the
actin cytoskeleton with phalloidin–rhodamine (Fig. 2C). DAPI staining
of viral and cellular DNA was used to identify virus-infected cells. In
VACVWR andMVA-F11L infected cells we observed the characteristic
loss of central actin stress ﬁbers, as described above. As expected, the
actin cytoskeleton remained unchanged uponMVA or mock infection.
These ﬁndings not only concur with the known function of F11, i.e.
binding and inhibiting RhoA signaling, but also further conﬁrm that
this gene function was successfully reintroduced into the MVA-F11L
recombinant viruses.
F11L expression does not extend the cellular host-range of MVA
The growth deﬁciency in mammalian cells is a characteristic
feature of VACV MVA. Carroll and Moss (1997) suggested classifying
cell lines as non-permissive, semi-permissive and permissive for MVA
replication based on the increase of infectious virus 72 h after a low
MOI infection. To test whether expression of F11L alone or in
combination with K1L can alter the replicative capacity of MVA, we
infected conﬂuent monolayers of CEF (permissive), BS-C-1 cells
(semi-permissive), and human HeLa or mouse NIH-3T3 cells (non-
permissive) with MVA-F11L, MVA-F11L-K1L, MVA-K1L, MVA and
Fig. 1. (A) Alignment of F11L ORF in MVA and VACVWR. The sequence identity is 96%. The F11L ORF of MVA is truncated by 33 bp compared to VACVWR, due to the indicated 15 bp
and 16 bp deletions, plus the 2 bp marked by a star that generate a nonsense mutation. Arrow: start codon. (B) Schematic illustration of the recombinant viral genomes. The F11L
locus was deleted as described in Materials and methods, and deletion III already exists in the MVA genome. Inserted F11L (black) and K1L (light grey) were derived via
recombination between vectors carrying cloned PCR-ampliﬁed VACV sequences and viral genomes. Dark grey boxes: repetitive LacZ sequences ﬂanking K1L. (C) PCR analysis of DNA
from cells infected with the indicated viruses. Top panel: full-length F11L fragment, generated using primers annealing to regions of F11L deleted in MVA (see A). Middle panel:
genomic MVA F11L locus ampliﬁed with ﬂanking primers annealing 479 bp upstream and 412 bp downstream of the F11L gene. Bottom panel: K1L-speciﬁc PCR fragments. Right:
schematic representation of the F11L gene and the positions of the primers (arrows) used for PCR. The black regions indicate deletions, and those marked with asterisks are already
deleted in the F11L sequences of MVA (see A). (D) Western blot analysis of F11L and K1L. HeLa cells were mock infected or infected with indicated viruses at a MOI of 5. Protein
lysates were prepared 5 hpi. β-actin detection served as a control for equal loading.
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monitor whether MVA replication is rescued by reinsertion of the K1L
host-range gene.
Disappointingly, after immunostaining the infected cell mono-
layers, we observed that virus plaques formed by MVA expressing
F11L were almost identical to MVA wild-type virus plaques. Underpermissive conditions we detected similar plaque sizes and morphol-
ogies. Reinsertion of F11L with or without K1L seemed to have no
inﬂuence on MVA spreading in HeLa and NIH-3T3 cells. Only single
infected NIH-3T3 or HeLa cells were detected 72 hpi with MVA-F11L
or MVA-F11L-K1L, as seen with the parental MVA (Fig. 3). Also on
semi-permissive (BS-C-1) or permissive cells (CEF) we observed no
Fig. 2. (A and B)Wound healing assays. Conﬂuent BS-C-1 cell monolayers, starved for two hours, were infected at a MOI of 10 with different MVA viruses, plus VACVWR as a positive
control. Wounds were then scratched into the monolayer. (A) Each wound was photographed 0 and 24 hpi with the indicated viruses. Bars indicate the initial wound width.
(B) Average number of cells entering the wound area 24 hpi. The plotted numbers represent eight independent experiments. (C) VACV induced rearrangements of the actin
cytoskeleton. HeLa cells were infected with the indicated viruses at a MOI of 20. Cells ﬁxed 4 hpi were stained for actin using phalloidin–rhodamine, and viral and cellular DNA using
DAPI. Typical cells are shown. Bars: 20 µm.
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Replication of MVA in RK-13 cells was only dependent on K1L
expression. In addition, insertion of F11L did not inﬂuence MVA
plaque morphology. Although the lack of F11L in VACV WR infection
negatively inﬂuences viral spread, addition of F11L seems to have no
inﬂuence on MVA infection in the cells we analyzed.
To analyze and quantify viral growth and spread in more detail, we
performed multiple-step growth analyses. We infected conﬂuent
monolayers of HeLa, NIH-3T3, BS-C-1, RK-13 and CEF cells with the
indicated viruses at aMOIof 0.05 anddeterminedviral titers 0, 12, 24, 48
and 72 hpi. Fig. 4 shows the average results of two independent
experiments. There is no replication advantage for the recombinant
MVA F11L viruses compared to MVA or MVAΔF11L. In HeLa and NIH-
3T3 cells MVA-F11L and MVA-F11L-K1L were unable to produce
progeny (Figs. 4B and D). In semi-permissive BS-C-1 cells MVA-F11L
and MVA-F11L-K1L showed 10–15 times increased titers similar to
those determined for MVA, MVAΔF11L or MVA-K1L by 72 hpi (Fig. 4A).There were no signiﬁcant differences in growth capacity between
MVA-F11L-K1L and MVA-K1L in RK-13 cells, both of which produced
about 1000-fold more progeny than the non-replicating MVA, MVA-
F11L or MVAΔF11L (Fig. 4C). Interestingly, at 72 hpi VACV WR
produced about 10-times more viruses in RK-13 cells than MVA-K1L
or MVA-F11L-K1L. As anticipated, in CEF cells we detected no
difference in viral titers between MVA and the recombinant viruses
(Fig. 4E). These results clearly show that reinsertion of functional F11L
alone or in combination with VACV K1L cannot change the general
growth restriction of MVA in mammalian cells.
F11L expression does not alter virion morphogenesis
To determine whether MVA with a functional F11L is capable of
undergoing additional processing steps in the virion maturation
process, we infected conﬂuent HeLa cell monolayers and analyzed
particle morphogenesis by electron microscopy at 24 hpi. In MVA
Fig. 3. Analysis of viral spread. Conﬂuent monolayers of BS-C-1, HeLa, NIH-3T3, RK-13 and CEF cells were infected with the indicated viruses at a MOI of 0.05. After the indicated time
points, cells were ﬁxed and immunostained with an anti-vaccinia serum. Arrows indicate single infected cells.
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Fig. 4.Multiple step-growth analysis. Monolayers of BS-C-1 (A), HeLa (B), RK-13 (C), NIH-3T3 (D) and CEF (E) cells were infected with the indicated viruses at a MOI of 0.05. Zero, 12,
24, 48 and 72 hpi cells and supernatants were harvested and virus titers were determined by titration on CEF. The average titers of two independent experiments are plotted at each
time point.
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as previously described (Sutter and Moss, 1992) (Fig. 5A). In MVA-
F11L infected cells, these accumulated particles showed no obvious
difference in virion morphology compared to MVA infected cells
(Fig. 5B). Fully matured viral particles were only detected in VACV
WR-infected HeLa cells (Fig. 5C). We conclude that expression of a
functional F11L in recombinant MVA infected HeLa cells is not
sufﬁcient to alter the phenotype of virion morphogenesis normally
observed with MVA wild-type infection.
Discussion
The host-range phenotype of MVA in HeLa and many other cells of
mammalian origin is characterized by a block in virionmorphogenesis
resulting in the accumulation of immature virions (Sutter and Moss,
1992). A similar phenotype was observed after F11L gene knock-
down in VACV WR-infected HeLa cells, provoking a defect in virion
morphogenesis and decreased viral growth (Valderrama et al., 2006).
This implicated a function of F11 in virion morphogenesis, which was
further supported by its co-localization with viral factories (Valder-
rama et al., 2006). Since MVA presumably does not encode a
functional F11 protein, we hypothesized that reconstituting the
F11L gene in MVA might beneﬁcially modulate MVA infection in
mammalian cells. In addition, we analyzed whether simultaneous co-
expression of the VACV host-range gene K1L could contribute to a
potential host-range function of F11.
Reintroduction of F11L gene sequences into MVA resulted in F11
protein expression, cell motility and rearrangement of the actin
cytoskeleton in infected cells. Migration of BS-C-1 cells was induced
after infection with F11L-positive viruses (VACV WR, MVA-F11L and
MVA-F11L-K1L). Although the number of migrating cells was
signiﬁcantly higher in MVA-F11L compared to MVA infected cells, it
clearly did not reach the cell numbers found after VACVWR infection(Fig. 2B). A rescue of actin remodeling by F11L expression in MVA
infection was ﬁrst described by Valderrama et al. (2006) and further
characterized by others (Morales et al., 2008). Our observed F11-
dependent VACV-induced remodeling of the actin cytoskeleton
(Fig. 2C) resembled MVA infected PtK-2 cells transiently expressing
F11L (Morales et al., 2008).
F11 induces cell motility by directly binding to the small GTPase
RhoA, inhibiting its downstream signaling (Valderrama et al., 2006).
However, Arakawa et al. (2007) speculated that two additional RhoA-
family proteins, Rac or Cdc42, involved in regulating the actin and
microtubule cytoskeleton, might be targeted by other viral proteins
encoded by VACVWR, and this could have an impact on virus-induced
cell motility. Although our MVA F11L recombinants did express the
same amounts of F11 as VACV WR, the fact that cell motility was not
induced to VACV WR levels (Figs. 2A and B) suggests that F11 is not
the only VACV protein involved in promoting cell migration. MVA
lacks many other genes found in VACV WR, any of which could
additionally inﬂuence cell migration.
One gene absent in MVA that we also analyzed here is K1L. The K1
protein interacts with cellular ACAP2, a GTPase activating protein
(GAP) for Arf6 (Bradley and Terajima, 2005). Although the ACAP2
interaction was not suggested as being linked to the host-range
function of K1 (Meng and Xiang, 2006), interestingly, Arf6 is involved
in actin remodeling and cell migration (Donaldson, 2003). Logically,
this would make K1 a good candidate for being involved in VACV
infection-induced cell migration. Our data, however, clearly indicate
that K1 is not the missing factor, since wound healing assays revealed
no differences between MVA-F11L and MVA-F11L-K1L infected cell
migration (Fig. 2B).
The central question in our study was whether restoring the F11L
gene in MVA would change its replicative capacity, hence possibly
overcoming MVA's host-range restriction in mammalian cells.
However, our multiple-step growth analyses in mammalian cells
Fig. 5. Analysis of virion morphogenesis. Conﬂuent HeLa cell monolayers were infected
with MVA (A), MVA-F11L (B) and VACV WR (C) at a MOI of 5. Cells were ﬁxed 24 hpi
and epon embedded slides were prepared. Bars: 1000 nm. Immature (IV) and
intracellular mature virions (IMV) are indicated, the latter only visible in the VACV
WR positive control.
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types investigated. Moreover, the permissiveness of the cells played
no role. This was further supported by electron microscopy of virions
in infected HeLa cells demonstrating that F11L gene expression in
MVA did not alter the characteristic phenotype of incomplete virion
morphogenesis under non-permissive conditions (Sutter and Moss,
1992). In contrast, the expected host-range rescue upon K1L insertion
was easily conﬁrmed, since both recombinant viruses expressing K1L
(MVA-K1L andMVA-F11L-K1L) productively replicated in RK-13 cells.
Morales et al. (2008) showed that a VACVWR F11L-deletionmutant
(VACVΔF11L) induced a smaller plaque size on BSC40 cell monolayers
than plaques induced by VACV WR. Therefore, we analyzed plaque
formationof the recombinantMVAonCEF (permissive forMVA), BS-C-1
(semi-permissive forMVA) aswell asRK-13,HeLa andNIH-3T3 cells (allnon-permissive forMVA). However, reconstituting F11L inMVA had no
inﬂuence on viral spread of recombinant MVA in the tested cell lines
(Fig. 3). This ﬁndingmay agree with our data from the highMOIwound
healing assays (Fig. 2), since it may be difﬁcult to ﬁnd a difference in
plaque size between F11L positive MVA and MVA wild-type, consider-
ing motility was only partially restored by F11L expression. Alterna-
tively, cell motility may not be the major factor in virus transmission.
The induction of actin tails was also shown to promote viral spread
(Ward andMoss, 2001) and though the ability ofMVA to form actin tails
was found to be conserved in CEF (Meiser et al., 2003) other data
suggested deﬁcient formation of actin tails upon infection of BSC-40
cells (Gallego-Gomez et al., 2003). Moreover, even upon high MOI
infection the overall growth kinetics of MVA are reduced in BS-C-1 cells
in comparison to VACV WR (Carroll and Moss, 1997) (our data not
shown). Thus, we believe that rather the kinetics of virus replication/
virion formation are the limiting factors inMVA spread at least in BS-C-1
cells.
Although not seen in our experiments, F11 function in VACV WR
was reported to contribute to VACV spread in vitro and in vivo, and
deletion of F11L in VACV was suggested as a potential approach to
improve the safety of VACV-based vaccines (Cordeiro et al., 2009).
Importantly, we show here that F11L alone cannot inﬂuence the
growth capacity of MVA in non-permissive cells. Restoring (an)other
VACV host-range gene(s) in addition to K1L is probably required to
relieve this restriction. Thus, it seems very likely that F11L gene
expression does not inﬂuence the in vivo attenuation of MVA. In
contrast, it is tempting to speculate that restoring F11L and possibly
the migration of MVA infected cells under non-permissive (in vivo)
conditions might inﬂuence vaccine immunogenicity.
Furthermore, by deleting the residual F11L sequence in MVA we
prove that this sequence is dispensable, since MVAΔF11L and MVA
wild-type behaved alike. We suggest it as an alternative site for
inserting exogenous sequences into the MVA genome, as was also
already shown for the F11L orthologue in fowlpoxvirus (Boulanger
et al., 2002).
In conclusion, the question posed by Valderrama et al. (2006) as to
whether F11 could contribute to overcoming the host-range restric-
tion of MVA in mammalian cells now clearly has a negatively answer,
and co-expression of the host-range gene K1L did not change the
outcome.
Materials and methods
Cells, viruses and antibodies
HeLa and BHK-21 cells were grown in Roswell Park Memorial
Institute medium (RPMI), NIH-3T3 and BS-C-1 cells in Dulbecco's
modiﬁed eagle medium (DMEM), and primary chicken embryo
ﬁbroblasts (CEF) and RK-13 cells in Eagle's basal medium (EMEM) at
37 °C in 10% CO2. CEF were freshly prepared and propagated for one
passage. All other cell lines were obtained fromATCC (CCL-2, CRL-1658,
CCL-10, CCL-37 and CCL-26). All media were supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin/streptomy-
cin and EMEM additionally with non-essential amino acids (Invitrogen,
Karlsruhe, Germany). Modiﬁed vaccinia virus Ankara II new (MVA) has
been described previously (Staib et al., 2003). Vaccinia virus strain
Western Reserve (VACV WR) was kindly provided by Bernard Moss,
National Institutes of Health, Bethesda, Md.
Polyclonal antibodies against F11 andK1were raised by immunizing
rabbits with two peptides (aa 11–23 RSKMLKRGSRKSSSIl and aa 105–
120 LDAVLDRDGNFRPADC for F11, 84–98 SGMDDSQFDDKGNTAL and
aa 243–258 HVEYKSDSYTKDLDIV for K1) derived from the VACV WR
sequence in case of F11 and VACV Copenhagen sequence in case of K1
protein (Eurogentec, Cologne, Germany). Monoclonal antibody against
β-Actin was purchased from Sigma-Aldrich (Taufkirchen, Germany).
Secondary antibodies against mouse and rabbit IgG, coupled to
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Homburg, Germany).
Construction of vector plasmids
All plasmid constructions were carried out using standard cloning
procedures (Sambrook et al., 1989). Oligonucleotides were purchased
from MWG Biotech (Ebersberg, Germany).
The K1L gene was ampliﬁed by PCR using VACV WR DNA as a
template. The following primers were used: 5′-AATTCTGCAGATCTCCT-
TAATATGGGTACG-3′ and 5′-AATTGGATCCAATGTTAACAAAAA-
TGTGGG-3′. The PstI and BamHI restriction sites (underlined) were
used to insert the ampliﬁed K1L gene into a transfer vector to generate
pLW9-E-K1L, which carries 500 bp up- and downstream sequences
ﬂanking deletion III of the MVA genome for recombination.
To delete most of the residual F11L sequences of MVA, the ﬂanking
sequences were ampliﬁed by PCR using the primers 5′-AAAA-
GCGGCCGCGTGAATAATTTCATTACCAAAG-3′ and 5′-AAAAGGGCCC-
TACTGTGAACTCCGCCGTAG-3′ for the downstream region, including
NotI andApaI restriction sites, and theprimers 5′-AAAAGAGCTCCAATG-
GAATGCAAAACCCCATAG-3′ and 5′-AAAAACGCGTCTACTAACGACCA-
TATTCCAG-3′ with SacI and MluI restriction sites (underlined) for the
upstream region. Both ampliﬁed DNA fragments were inserted into the
pΔK1L plasmid (Staib et al., 2000) to obtain the F11L deletion plasmid
pΔF11L.
Functional F11L was ampliﬁed by PCR using VACV WR DNA as a
template and the primers 5′-ATAAGAATGCGGCCGCATACGTTAG-
TAGCTCTTATAAAG-3′ and 5′-TTGGCGCGCCGGCAACACCCATTTATTG-
TAC-3′ containing NotI and AscI restriction sites (underlined) for
insertion into a MVA deletion III transfer vector carrying K1L
surrounded by repetitive sequences, to form pGSV23-F11L. Genomic
DNA was isolated from infected cells using the DNeasy Blood & Tissue
kit (Qiagen, Hilden, Germany) according to the manufacturer's
instructions. Polymerase chain reaction (PCR) was carried out using
Taq polymerase (Roche, Germany) according to the manufacturer's
instructions and was veriﬁed by sequencing.
Generation of recombinant viruses
Conﬂuent BHK-21 cells were grown in 6-well tissue culture plates
and infected with MVA at a multiplicity of infection (MOI) of 0.05.
1.5 hours post infection (hpi) either pLW9-E-K1L or pΔF11L were
transfected with lipofectamine 2000 (Invitrogen, Karlsruhe,
Germany) using the procedure recommended by the manufacturer.
48 h later, cells and supernatant were harvested, freeze-thawed three
times and homogenized in a cup sonicator (Sonopuls HD 200;
Bandelin, Berlin, Germany). The subsequent procedure has been
described previously (Staib et al., 2000).
MVA-F11L and MVA-F11L-K1L were generated by infecting BHK-
21 cells with MVAΔF11L and transfection of pGSV23-F11L as
described above. The K1L gene was either lost by repeated plaque
puriﬁcation of recombinant MVA-F11L-K1L on CEF due to its ﬂanking
repetitive sequences, or preserved by passaging on RK-13 cells. Viral
DNA from cloned MVA isolates was routinely analyzed by PCR as
described previously (Staib et al., 2000). The presence of the original
F11L locus was analyzed using the primers 5′-AAAAGGGCCCTACTGT-
GAACTCCGCCGTAG-3′ and 5′-AAAAACGCGTCTACTAACGACCATATTC-
CAG-3′, which were already used for cloning the ﬂanks of pΔF11L. To
prove whether the inserted full-length F11L is present in MVA-F11L
and MVA-F11L-K1L we used the primers 5′-TGAATTGTTTCTTTTA-
GAAGTG-3′ and 5′-AGGAGATACTATCGTCAGTA-3′ which anneal to
regions of the F11L sequence that are deleted in the residual F11L
locus of MVA (Fig. 1A). The presence of K1L was analyzed using the
primers 5′-ACGTGCGTCTAGTATGTAC-3′ and 5′-TCTCAATGTCTTTAT-
TATCTATA-3′.Western blot analysis
Conﬂuent monolayers of HeLa cells were infected at a MOI of 10
with the appropriate viruses. At 5 hpi cell lysates were prepared as
described previously (Ludwig et al., 2006) and separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Proteins were electroblotted onto a PVDF membrane (Bio-Rad,
Munich, Germany). After blocking, membranes were incubated with
primary antibodies at 4 °C overnight. After washing, the blots were
incubated with secondary antibodies for one hour at room temper-
ature. Detection of ﬂuorescence was performed with the Odyssey
Infrared Imaging System (LI-COR Biosciences, Bad Homburg,
Germany).
Wound healing assay
Conﬂuent monolayers of BS-C-1 cells in 6-well cell culture dishes
were starved for 2 h and afterwards infectedwith VACV at aMOI of 10.
After virus adhesion for one hour, several wounds were scratched into
the cell monolayer with a transparent tip. Cells were washed three
times with PBS before adding cell culture medium without serum.
Wounds were photographed (DX40 camera, Kappa, Gleichen,
Germany) directly and 24 h later at marked positions with phase con-
trast at a magniﬁcation of 100 (Axiovert 40 CLT, Carl Zeiss, Göttingen,
Germany).
Fluorescence microscopy
HeLa cells were grown on coverslips and infected at a MOI of 20.
20 min after infection, cells were washed three times with warm,
serum-free medium to ensure synchronized infection. 3 hpi cells were
ﬁxed with 3.7% paraformaldehyde in PBS for 15 min, afterwards
washed twice with PBS and then permeabilized for 10 min with 0.1%
Triton-X-100 in PBS at room temperature. Cells were blocked for
30 min with 5% BSA in PBS to prevent unspeciﬁc binding. The actin
cytoskeleton was stained with phalloidin–rhodamine (Chemicon
International, Temecula, USA) and DNA with 4′,6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich, Steinheim, Germany) for 45 min
in 2% BSA in PBS. After washing three times with PBS coverslips were
mounted using mowiol. Confocal microscopy was performed using a
LSM510 META (Carl Zeiss, Göttingen, Germany) at a magniﬁcation of
630. Images were processed using Zeiss LSM image browser version
3.5.
Electron microscopy
Conﬂuent HeLa cells grown in 10 cm cell culture dishes were mock
infected or infected with VACV at a MOI of 5. After one hour of viral
adhesion the cell media was renewed. 24 hpi cells were ﬁxed for
45 min with 2.5% glutaraldehyde in medium. Epon embedding and
staining procedures have been described previously (Steidl et al.,
2004). Scans were documented with the help of a transmission
electron microscope (Type 902, Carl Zeiss, Göttingen, Germany) with
a slow-scan CCD camera.
Analysis of viral growth and plaque formation
Conﬂuent monolayers of indicated cell lines or primary CEF were
grown in 6-well plates and infected with VACV at a MOI of 0.05. For
multiple-step growth curves, viruses were adsorbed to the cells for
1 h at 37 °C, washed two times and cultivated at 37 °C in media with
2% serum. Zero, 12, 24, 48 and 72 hpi cells and supernatants were
harvested, freeze-thawed and sonicated three times. Virus titers were
determined on CEF cells following standard procedures as described
previously (Hornemann et al., 2003).
239J. Zwilling et al. / Virology 404 (2010) 231–239For spreading analysis, immunostaining of infected cells was
performed as described previously (Staib et al., 2004). Brieﬂy, cells
were infected with the indicated viruses at a MOI of 0.05. 24, 48 and
72 hpi cells were ﬁxed with ice-cold methanol/acetone, blocked with
PBS containing 3% FCS and stained with polyclonal VACV antiserum
(Abgene, Epsom, United Kingdom) and an HRP-conjugated secondary
antibody. Detection was performed using 0.3% dianisidine solution in
PBS with 0.01% H2O2 as the substrate. Pictures were taken by phase
contrast microscopy (Axiovert 40 CLT, Carl Zeiss, Göttingen,
Germany) with 100-fold magniﬁcation.
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